

Amanda Keddy in the new
Stewart E. Allen Hybrid OR

WE ARE
BOLDLY TRANSFORMING CARE

Queen Elizabeth II Health Sciences Centre Foundation

Contents

	Page
Independent auditor's report	1-2
Statements of revenue, expenses and fund balances	3
Balance sheet	4
Statement of cash flows	5
Notes to the financial statements	6-12

Independent auditor's report

Grant Thornton LLP
Nova Centre, North Tower
Suite 1000, 1675 Grafton Street
Halifax, NS
B3J 0E9

T +1 902 421 1734
F +1 902 420 1068

To the members of the Board of Directors of the
Queen Elizabeth II Health Sciences Centre Foundation

Opinion

We have audited the financial statements of the Queen Elizabeth II Health Sciences Centre Foundation (the "Foundation"), which comprise the balance sheet as at March 31, 2023, and the statements of revenue, expenses and changes in fund balances, and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Queen Elizabeth II Health Sciences Centre Foundation as at March 31, 2023, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Foundation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



Halifax, Canada
June 21, 2023

Chartered Professional Accountants

Queen Elizabeth II Health Sciences Centre Foundation

Statements of revenue, expenses and fund balances

Year Ended March 31

	Undesignated fund	Designated fund	Endowment fund	2023 \$	2022 \$
Fundraising programs revenue					
Annual programs	531,798	1,156,356	29,140	1,717,294	1,850,591
Planned giving	301,442	1,065,312	2,000	1,368,754	2,114,481
Major gifts	53,264	5,863,844	549,776	6,466,884	4,600,922
Special events (note 3)	-	2,391,371	-	2,391,371	2,577,101
Total fundraising programs revenue	886,504	10,476,883	580,916	11,944,303	11,143,095
Fundraising program costs	(2,983,036)	(622,353)	-	(3,605,389)	(3,657,562)
Net fundraising	(2,096,532)	9,854,530	580,916	8,338,914	7,485,533
Gaming income, net (note 4)	8,819,853	-	-	8,819,853	10,443,917
Investment income (loss), net (note 5)	643,050	-	(143,618)	499,432	656,738
General and administrative expenses	(2,220,772)	-	-	(2,220,772)	(2,005,305)
Government grants and subsidies (note 6)	-	-	-	-	408,442
Excess of revenue over expenses	5,145,599	9,854,530	437,298	15,437,427	16,989,325
Fund balances, beginning of year	7,903,666	36,948,349	45,449,030	90,301,045	85,046,967
Excess of revenue over expenses	5,145,599	9,854,530	437,298	15,437,427	16,989,325
Grants and charitable activity (note 7)	(177,753)	(12,364,950)	(963,434)	(13,506,137)	(11,735,247)
Remeasurements of Employee future benefits	36,075	-	-	36,075	-
Interfund transfers (note 8)	(1,295,782)	1,480,782	(185,000)	-	-
Fund balances, end of year	11,611,805	35,918,711	44,737,894	92,268,410	90,301,045

See accompanying notes to the financial statements.

Queen Elizabeth II Health Sciences Centre Foundation

Balance sheet

Year Ended March 31

2023

2022

	Undesignated fund	Designated fund	Endowment fund	\$ Total	\$ Total
Assets					
Current					
Cash	7,838,658	16,819,985	2,133,581	26,792,224	24,511,614
Cash held for lottery	6,855,461	-	-	6,855,461	7,241,034
Receivables	524,489	364,998	56,634	946,121	915,129
Prepays and other (note 4)	<u>4,128,552</u>	<u>23,055</u>	-	<u>4,151,607</u>	<u>3,833,172</u>
	19,347,160	17,208,038	2,190,215	38,745,413	36,500,949
Investments, at market value (note 9)	-	23,102,091	42,779,755	65,881,846	63,888,290
Capital assets (note 10)	<u>254,622</u>	-	-	<u>254,622</u>	<u>247,516</u>
	<u>19,601,782</u>	<u>40,310,129</u>	<u>44,969,970</u>	<u>104,881,881</u>	<u>100,636,755</u>

Liabilities and fund balances


Liabilities

Current

Unearned revenue	1,952,151	108,562	-	2,060,713	2,886,945
Payables and accruals	<u>5,278,680</u>	<u>4,282,856</u>	<u>232,076</u>	<u>9,793,612</u>	<u>6,641,867</u>
	7,230,831	4,391,418	232,076	11,854,325	9,528,812
Employee pension plan benefits (note 11)	759,146	-	-	759,146	806,898
Fund balances	<u>11,611,805</u>	<u>35,918,711</u>	<u>44,737,894</u>	<u>92,268,410</u>	<u>90,301,045</u>
	<u>19,601,782</u>	<u>40,310,129</u>	<u>44,969,970</u>	<u>104,881,881</u>	<u>100,636,755</u>

Commitments (note 12)

On behalf of the Board

 Director

 Director

See accompanying notes to the financial statements.

Queen Elizabeth II Health Sciences Centre Foundation

Statement of cash flows

Year Ended March 31	2023	2022
Increase (decrease) in cash	\$	\$
Operating		
Excess of revenue over expenses	15,437,427	16,989,325
Fund disbursements	(13,506,137)	(11,735,247)
Amortization	99,576	102,654
Realized income and gains on investments	(2,229,396)	(3,045,076)
Unrealized change in market value of investments	2,393,801	2,397,447
	<u>2,195,271</u>	<u>4,709,103</u>
Changes in non-cash working capital		
Receivables	(30,992)	(114,232)
Prepays and other	(318,435)	(3,332,926)
Unearned revenue	(826,232)	(1,255,232)
Payables and accruals	3,151,745	(1,185,163)
Employee Future Benefits	(11,677)	(10,089)
Subtotal	<u>1,964,409</u>	<u>(5,897,642)</u>
	<u>4,159,680</u>	<u>(1,188,539)</u>
Investing		
Net additions to investments	(2,157,961)	(3,350,477)
Net additions fixed assets	(106,682)	-
Net change in cash held for lottery	385,573	3,070,750
	<u>(1,879,070)</u>	<u>(279,727)</u>
Net increase (decrease) in cash	2,280,610	(1,468,266)
Cash		
Beginning of the year	<u>24,511,614</u>	<u>25,979,880</u>
End of the year	<u>26,792,224</u>	<u>24,511,614</u>

See accompanying notes to the financial statements.

Queen Elizabeth II Health Sciences Centre Foundation

Notes to the financial statements

March 31, 2023

1. Nature of operations

The Queen Elizabeth II Health Sciences Centre Foundation Inc. (the “Foundation”) is a not-for-profit organization established to raise and receive funds to support patient care, education and research at the Queen Elizabeth II Health Sciences Centre (the “Health Centre”). The Foundation is a registered charity under the Income Tax Act and as such, is not subject to income tax.

2. Summary of significant accounting policies

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations (“ASNPO”). The significant policies are detailed as follows:

Fund accounting

The Foundation follows the Restricted Fund method of accounting for donations.

The Undesignated Fund represents the Foundation’s general fundraising, gaming, investment and administrative activities. The Undesignated Fund reports amounts received for which a specific purpose has not been identified by the donor. The Undesignated Fund represents unrestricted resources available for immediate purposes.

The Designated Fund represents amounts received from donors and special events to be used for an identified purpose as specified by the donor on the receipt of the contributions or as determined by the Board of Directors.

The Endowment Fund represents amounts either received from a donor or internally restricted by the Board that require that the principal be invested by the Foundation permanently. Investment income generated on endowments must be used in accordance with the various purposes established by the donor or the Board of Directors. The Foundation has established an Endowment Management Policy and an Investment Policy Statement to manage endowments.

Revenue recognition

Unrestricted donations are recognized as revenue of the Undesignated Fund when received. The gross amount of gaming revenue received for lottery ticket sales, net of any expenses incurred to date, is recorded as cash held for lottery and unearned revenue until the lottery draw occurs and the remaining expenses are paid.

Restricted donations are recognized as revenue of the Designated Fund. Donations are considered restricted when specifically restricted by the donor and when received for a specific campaign.

Contributions where the capital resource is to be maintained permanently are recognized as revenue of the Endowment Fund.

Donated insurance policies are recognized into income at their estimated fair value on the date ownership is transferred to the Foundation.

Government grants and subsidies

The Foundation recognizes government grants and subsidies toward current operating expenses in the Unrestricted Fund of the statement of operations. When government assistance received relates to the acquisition of capital assets, the Foundation deducts the assistance from the cost of the related capital asset. When government assistance received relates to future expenses or future capital purchases, the Foundation defers the assistance and recognizes it in the statement of operations as the related expenses are incurred or against capital assets as capital purchases are made. Contributions from federal, provincial or municipal governments or their agencies that support fundraising projects are recognized as fundraising revenue in accordance with revenue recognition policies.

Queen Elizabeth II Health Sciences Centre Foundation

Notes to the financial statements

March 31, 2023

2. Summary of significant accounting policies (continued)

Capital assets

Capital assets are recorded at cost in the Undesignated Fund and amortized using the straight-line method over the estimated useful lives of the assets as follows:

Leasehold improvements	Remaining lease term
Office equipment and furniture	5 years
Computer equipment	5 years

Financial instruments

Financial instruments are recorded at fair value on initial recognition. Financial instruments that are quoted in an active market such as equities and bonds are subsequently measured at fair value. All other financial instruments are subsequently measured at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Foundation has elected to carry investments in pooled funds at fair value with changes in fair value recognized in net income in the period in which they arise. Fair value is measured as the closing price of an investment on an active quoted market.

Investments in pooled funds with underlying investments in equities or bonds and debentures or short term deposits and cash are valued based on the latest unit values supplied by the external pooled fund investment manager. Investments in pooled funds also include alternative investments, which include real estate assets. Real estate assets held within pooled funds are independently appraised by third parties in determining the net asset value reported by the fund manager. As part of the Foundation's investment management strategy, the Foundation is committed to future investment in loan portfolios. This represents the Foundation's proportionate share of underlying net assets at fair value determined using closing market prices.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs. These costs are amortized using the effective interest rate method.

The financial instruments measured at amortized cost are cash, cash held for lottery, receivables, prepaids and other assets, unearned revenue, and payables and accruals.

For financial assets measured at cost or amortized cost, the Foundation regularly assesses whether there are any indications of impairment. If there is an indication of impairment, and the Foundation determines that there is a significant adverse change in the expected timing or amount of future cash flows from the financial asset, it recognizes an impairment loss in the statement of revenue, expenses and fund balances. Any reversals of previously recognized impairment losses are recognized in operations in the year the reversal occurs.

All undesignated and designated investment income earned is recognized as revenue of the Undesignated Fund. Endowment investment income is recognized as revenue of the Endowment Fund.

The Foundation is exposed to various risks through its financial instruments. The following analysis provides a measure of the Foundation's risk exposure as at the date of the financial statements.

i) Credit risk

The Foundation is exposed to credit risk in the event of non-performance by counterparties to financial instruments. The Foundation mitigates this risk by monitoring the performance of the individual investments held in alternative funds and ensuring compliance by the investment manager with the investment policies of the Foundation. The Foundation is of the view it is not exposed to significant credit risk.

Queen Elizabeth II Health Sciences Centre Foundation

Notes to the financial statements

March 31, 2023

2. Summary of significant accounting policies (continued)

Financial instruments (continued)

ii) Liquidity risk

Liquidity risk is the risk that the Foundation will not be able to pay financial liabilities as they come due. The Foundation's liquidity risk is managed on a daily basis in accordance with the Foundation's Investment Policy Statement. The Foundation maintains sufficient cash balances to meet its immediate liabilities. The majority of invested assets held by the Foundation are invested in securities that are traded in an active market and can be readily disposed of as liquidity needs arise. Alternative investments are only held in the Endowment Fund with very limited expectation that liquidity will be required on short notice.

iii) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. For purposes of this disclosure, the Foundation segregates market risk into three categories: interest rate risk, currency risk and other price risk.

Interest rate risk

Interest risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of the changes in market interest rates. The Foundation is not exposed to any significant interest rate risk.

Currency risk

The Foundation's functional currency is the Canadian dollar. Foreign currency risk arises from the Foundations investments that are denominated in a foreign currency. Fluctuations in the relative value of foreign currencies against the Canadian dollar can result in positive or negative effect on the fair value of the investments. The Foundation is not exposed to any significant currency rate risk.

Other price risk

Other price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices, other than those occurring from interest rate risk or currency risk. Securities held for trading are carried at fair value and, as such, impact earnings as changes occur. Investments held in alternative funds expose the Foundation to price risk, however this is sufficiently mitigated through pooled investments and diversification of portfolios.

These risks are mitigated through the use of professional investment managers, and appropriate asset, sector and geographic allocation.

Use of estimates

Management reviews the carrying amounts of items in the financial statements at each balance sheet date to assess the need for revision or any possibility of impairment. Many items in the preparation of these financial statements require management's best estimate. Management determines these estimates based on assumptions that reflect the most probable set of economic conditions and planned courses of action. These estimates are reviewed periodically and adjustments are made to net income as appropriate in the year they become known. Items subject to significant management estimates include unearned revenue, unfunded pension plan liabilities, life insurance policies, and fair value of investments.

Donated materials and services

Donated materials and services are recorded in the financial statements when the fair value of these items can be reasonably estimated. The Foundation has recognized \$73,867 (2022 - \$187,151) as donated materials and services during the year. Donated materials included in capital assets for the Health Centre are comprised of equipment and furniture, as well as advertising, media coverage, and promotional items.

Cash

Cash in the bank is currently in an interest bearing account yielding interest at prime less 1.5% for closing daily balances.

Queen Elizabeth II Health Sciences Centre Foundation

Notes to the financial statements

March 31, 2023

2. Summary of significant accounting policies (continued)

Employee future benefits

The Foundation has a multi-employer defined benefit plan and registered retirement savings plan, both of which have been accounted for as defined contribution plans.

The Foundation also has a Supplemental Employee Pension Plan, for which it accrues the estimated liability payable in subsequent years according to its policy. The retirement benefit is actuarially determined using the projected benefit method prorated on service.

3. Special events

	<u>2023</u>	<u>2022</u>
	\$	\$
Ride for Cancer		
Gross revenue	2,124,098	2,301,750
Direct expenses	<u>493,735</u>	<u>593,039</u>
	<u>1,630,363</u>	<u>1,708,711</u>
Jordan Boyd Celebrity Hockey Challenge		
Gross revenue	267,273	245,851
Direct expenses	<u>108,827</u>	<u>92,454</u>
	<u>158,446</u>	<u>153,397</u>
Heart Heroes		
Gross revenue	-	29,500
Direct expenses	<u>-</u>	<u>-</u>
	<u>-</u>	<u>29,500</u>

4. Gaming income, net

	<u>2023</u>	<u>2022</u>
	\$	\$
Revenue		
Home Lottery	24,805,280	25,172,352
Workin' To Win and 50/50 Raffle	<u>131,667</u>	<u>152,824</u>
	<u>24,936,947</u>	<u>25,325,176</u>
Expenses		
Home Lottery	16,063,986	14,828,151
Workin' To Win and 50/50 Raffle	<u>53,108</u>	<u>53,108</u>
	<u>16,117,094</u>	<u>14,881,259</u>
	<u>8,819,853</u>	<u>10,443,917</u>

The Foundation has purchased land outright, advanced deposits secured by mortgages on land as part of purchase and sale agreements and made progress payments on construction contracts of \$4,029,844 (2022 - \$3,771,140) related to future QEII Home Lottery programs which has been included in prepaids and other assets.

The Foundation has entered into future commitments of \$4,882,505 (2022 - \$3,730,175) for the construction of properties for the QEII Home Lottery.

5. Investment income, net

Investment income includes interest, dividends and realized gains (losses) and changes in fair value.

Investment expenses consist of management fees and investment consulting fees. Management fees are paid in accordance with Investment Management Agreements based the on the average daily market value of assets under management.

	<u>2023</u>	<u>2022</u>
	\$	\$
Revenue	942,921	1,071,598
Expenses	<u>443,489</u>	<u>414,860</u>
	<u>499,432</u>	<u>656,738</u>

Queen Elizabeth II Health Sciences Centre Foundation

Notes to the financial statements

March 31, 2023

6. Government grants and subsidies

Due to COVID-19 the Government of Canada implemented the COVID-19 Economic Response Plan. Under this plan the Foundation was eligible for the Canada Wage Subsidy (CEWS), the 10% Temporary Wage Subsidy (TWS) and the Canada Emergency Rent Subsidy (CERS). Total subsidies received under these programs amount to \$Nil (2022 - \$408,442).

7. Grants and charitable activity

The following highlight significant projects for which grants were issued during the year.

Undesignated Fund

	<u>2023</u>	<u>2022</u>
	\$	\$
Prostate Biopsy Equipment	164,080	193,091
Echocardiography	-	198,078
Other	<u>13,673</u>	<u>26,442</u>
	<u>177,753</u>	<u>417,611</u>

Designated Fund

Personalized radiotherapy	2,961,287	-
Orthopaedic surgical robot	1,851,633	-
Spinal robotic system	1,713,623	-
Robotics Surgical Systems	670,369	883,726
Next generation sequencing	795,006	-
Hybrid Interventional Operating Room	572,339	3,427,661
COVID Recovery Fund	459,303	272,522
Translating Research Into Care (TRIC)	300,000	300,000
CT SIM	267,235	-
Interventional Radiology Suites	234,355	974,625
Electrophysiology laboratory	166,809	-
Tissue Morcellator	160,494	-
Jordan Boyd Memorial Fund – Inherited heart Disease research	160,000	-
Ride for Cancer - Leukemia and Lymphoma Society	150,000	150,000
rTMS (Repetitive Transcranial Magnetic Stimulation)	107,497	188,554
Neurosurgery Research	105,665	102,162
Diversity in health care	100,000	-
Text4Support project	100,000	-
Gallium Scanner	95,000	95,000
Capital Equipment Support Grant	-	1,000,000
Colposcopy Equipment	-	331,459
E-Mental Health	-	253,196
Staying Connected Mental Health Project	-	218,104
Aortic Research	-	200,000
Eye Care Centre – Corneal Topography & Pupilometer	-	180,503
Heart Health Innovation Fund Grants	-	178,489
Cancer Research – AIF Program	-	153,540
Nova Scotia Cancer Centre – EBUS and Bronchoscope	-	119,866
Inflammatory Bowel Disease Research	-	99,600
Other	<u>1,301,121</u>	<u>1,312,629</u>
	<u>12,364,950</u>	<u>10,441,636</u>

Queen Elizabeth II Health Sciences Centre Foundation

Notes to the financial statements

March 31, 2023

Endowment Fund

	<u>2023</u>	<u>2022</u>
	\$	\$
Research Chairs	678,000	581,000
Research scholars	184,613	250,132
Other	<u>100,821</u>	<u>44,868</u>
	<u>963,434</u>	<u>876,000</u>
	<u>13,506,137</u>	<u>11,735,247</u>

8. Interfund transfers

During the year, funds were transferred between the Undesignated, Designated, and Endowment Funds as follows:

	<u>Undesignated</u>	<u>Designated</u>	<u>Endowment</u>
	\$	\$	\$
Board approved fund designations	(1,338,000)	1,338,000	-
Other Transfers	<u>42,218</u>	<u>142,782</u>	<u>(185,000)</u>
	<u>(1,295,782)</u>	<u>1,480,782</u>	<u>(185,000)</u>

9. Investments, at market value

The Foundation invests in accordance with its investment policies approved by the Board of Directors. The policies provide financial objectives, asset mix and permitted investment guidelines for each investment account type.

The nature and fair value of the underlying investments held for each investment account are as follows:

	<u>2023</u>	<u>2022</u>
	\$	\$
Designated		
Cash and short term deposits	3,506,211	3,536,212
Fixed income	8,593,991	7,581,089
Equities	<u>11,001,889</u>	<u>12,245,817</u>
	<u>23,102,091</u>	<u>23,363,118</u>
Endowment		
Fixed income	3,752,585	3,095,977
Core plus fixed income	2,204,749	2,264,864
Mortgages	2,347,197	-
Equities	29,647,736	30,444,127
Real estate assets	<u>4,827,488</u>	<u>4,720,204</u>
	<u>42,779,755</u>	<u>40,525,172</u>
	<u>65,881,846</u>	<u>63,888,290</u>

10. Capital assets

	<u>Cost</u>	<u>Accumulated amortization</u>	<u>2023 Net book value</u>	<u>2022 Net book value</u>
	\$	\$	\$	\$
Leasehold improvements	293,811	198,146	95,665	126,121
Office equipment and furniture	246,820	233,814	13,006	25,906
Computer equipment	<u>354,855</u>	<u>208,904</u>	<u>145,951</u>	<u>95,489</u>
	<u>895,486</u>	<u>640,864</u>	<u>254,622</u>	<u>247,516</u>

Queen Elizabeth II Health Sciences Centre Foundation

Notes to the financial statements

March 31, 2023

11. Employee pension plan benefits

The Foundation has an RRSP matching agreement with select employees employed prior to March 1, 2007. The Foundation will match an employee's RRSP contribution up to a maximum of 5% of the employee's salary.

The Foundation is a member of a multi-employer defined benefit pension plan administered by Health Association Nova Scotia ("HANS"). The most recent actuarial valuation for funding purposes as at July 1, 2021 indicated a funding ratio of 109%. Existing employees that are enrolled in the RRSP matching agreement can choose to join the Nova Scotia Health Employees Pension Plan ("NSHEPP") or stay with the original Plan. New employees, after March 1, 2007, must join the NSHEPP.

During 2002, the Foundation established an unfunded Supplemental Pension Plan arrangement also administered by HANS, covering certain of its senior management employees. The benefits are based on years of service and final average salary. The most recent actuarial valuation for funding purposes on this plan was conducted on April 12, 2023 for the March 31, 2023 year end.

The total cost for these plans recognized in the current year is \$294,826 (2022 - \$280,588).

The funded status of the Supplemental Pension Plan is as follows:

	<u>2023</u>	<u>2022</u>
	\$	\$
Accrued benefit obligation and liability	<u>759,146</u>	<u>806,898</u>

The Foundation has sufficient undesignated net assets to meet the current obligations of the Supplemental Pension Plan.

12. Commitments

The Foundation rents office spaces under an operating lease which expires on April 30, 2026. The minimum lease commitments relating to this for the next four years ending March 31 are as follows:

2024	\$ 293,007
2025	284,228
2026	277,957
2027	23,163

The Foundation issues non-binding multi-year commitments to the QEII Health Sciences Centre (Nova Scotia Health) to support the purchase of equipment and technology, improve patient care and to support research and education initiatives. The total of these commitments at March 31, 2023 is \$15,713,079 (2022 - \$6,854,914).

13. Comparative figures

Certain of the comparative figures for the prior year have been reclassified to conform to the financial statement presentation adopted for the current period.



We are challenging the status quo.

Transformed health. Transformed lives. This is our vision. For more than 25 years – with incredible support from the community – the QEII Foundation has been advancing health care through the QEII Health Sciences Centre by funding new technologies, medical research, innovation and professional education.

We are on a mission to elevate health care to unprecedented heights at Atlantic Canada's largest adult health sciences centre and beyond – impacting nearly every QEII care area and over one million patient visits each year.